NCT07174011View on ClinicalTrials.gov

Evaluation of the Efficacy and Safety of Oral Roflumilast Versus Intralesional Corticosteroids Injection (ILCs) in the Treatment of Alopecia Areata

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 12, 2025

Primary Completion Date

May 20, 2025

Study Completion Date

August 20, 2025

Conditions

AlopeciaAlopecia Areata

Interventions

DRUG

Roflumilast

Phosphodiesterase-4 (PDE4) inhibitor assigned to arm A

DRUG

intralesional steroid

intralesional injection of corticosteroid

Trial Locations (1)

13114

Cairo University, Giza

All Listed Sponsors

lead

Cairo University

OTHER

NCT07174011 - Evaluation of the Efficacy and Safety of Oral Roflumilast Versus Intralesional Corticosteroids Injection (ILCs) in the Treatment of Alopecia Areata | Biotech Hunter | Biotech Hunter